934178-97-9

Usage

Uses

Used in Pharmaceutical Industry:
7-Tosyl-7H-Pyrrolo[2,3-d]pyrimidine-5-boronic acid pinacol ester is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and reactivity make it a valuable component in the development of new drugs, particularly those targeting specific biological pathways or receptors.
Used in Organic Synthesis:
In the realm of organic synthesis, 7-Tosyl-7H-Pyrrolo[2,3-d]pyrimidine-5-boronic acid pinacol ester serves as a versatile reagent. Its capacity to engage in Suzuki-Miyaura cross-coupling reactions and other organic transformations allows chemists to construct complex molecular architectures with precision and efficiency.
Used in Research and Development:
7-Tosyl-7H-Pyrrolo[2,3-d]pyrimidine-5-boronic acid pinacol ester is employed as a research tool in academic and industrial laboratories. Its unique properties and reactivity make it an ideal candidate for exploring new chemical reactions and mechanisms, as well as for the development of novel synthetic methodologies.
Used in Drug Design and Discovery:
7-Tosyl-7H-Pyrrolo[2,3-d]pyrimidine-5-boronic acid pinacol ester is leveraged in drug design and discovery processes. Its structural features and reactivity enable the creation of diverse chemical libraries, which can be screened for potential drug candidates with specific therapeutic properties.
Used in Chemical Modification:
7-Tosyl-7H-Pyrrolo[2,3-d]pyrimidine-5-boronic acid pinacol ester is also used for the selective chemical modification of the pyrrolopyrimidine core, facilitated by the protective tosyl group. This selective functionalization allows for the fine-tuning of the compound's properties and its potential applications in various chemical and biological contexts.

InChI:InChI=1/C13H19BN2O3/c1-12(2,17)13(3,4)19-14(18)10-7-9-5-6-15-11(9)16-8-10/h5-8,17-18H,1-4H3,(H,15,16)

Upstream product

• 934178-96-8 5-bromo-7-(p-toluenesulfonyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 73183-34-3 bis(pinacol)diborane 
• 98-59-9 p-toluenesulfonyl chloride 
• 271-70-5 7H-pyrrolo[2,3-d]pyrimidine 

Relevant academic research and scientific papers

INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF

The invention provides a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the manufacture of medicaments for treating of influenza.

INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF

The invention provides a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.

Influenza virus replication inhibitor and application thereof

The invention provides a type of compounds serving as an influenza virus replication inhibitor, a preparation method of the compounds, a pharmaceutical composition comprising the compounds, and application of the compounds and the pharmaceutical composition thereof in treatment of influenza.

HETEROCYCLIC INDOLES FOR USE IN INFLUENZA VIRUS INFECTION

The current invention relates to a compound of formula (I) which can be used for the treatment of, or against viral influenza infections.

PYRROLOPYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION

The invention relates to compounds having the structure of formula (I) which can be used for the treatment of or against influenza infections.

ARYL SUBSTITUTED PYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION

The invention relates to compounds having the structure of formula (I) which can be used for the treatment of or against influenza infections.

Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases

While several therapeutic options exist, the need for more effective, safe, and convenient treatment for a variety of autoimmune diseases persists. Targeting the Janus tyrosine kinases (JAKs), which play essential roles in cell signaling responses and can contribute to aberrant immune function associated with disease, has emerged as a novel and attractive approach for the development of new autoimmune disease therapies. We screened our compound library against JAK3, a key signaling kinase in immune cells, and identified multiple scaffolds showing good inhibitory activity for this kinase. A particular scaffold of interest, the 1H-pyrrolo[2,3-b]pyridine series (7-azaindoles), was selected for further optimization in part on the basis of binding affinity (Ki) as well as on the basis of cellular potency. Optimization of this chemical series led to the identification of VX-509 (decernotinib), a novel, potent, and selective JAK3 inhibitor, which demonstrates good efficacy in vivo in the rat host versus graft model (HvG). On the basis of these findings, it appears that VX-509 offers potential for the treatment of a variety of autoimmune diseases.

DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES

The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.